Biogen Snaps Up $5.6 Billion Deal. Why Shares Fell. - Investor's Business Daily

Biogen Snaps Up $5.6 Billion Deal. Why Shares Fell.  Investor's Business DailyBiogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology  BiogenBiogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push  CNBCBiogen makes $5.6B bet on Apellis Pharma  AxiosBiogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds  Fierce Pharma